SquareMind raises $18M for robotic dermatology platform
AI-summarised brief · reviewed before publication
SquareMind has raised $18 million to automate skin cancer detection with its Swan robotic platform, which uses AI and robotics for dermoscopic imaging. The platform provides physicians with structured data to track and identify melanomas efficiently. The funding will support commercial, engineering, and customer support teams for a near-term launch in the US and Europe, where demand for skin exams is high.
💡 Why It Matters
- · SquareMind's technology addresses the pressing issue of long waitlists and high patient volumes in dermatology, freeing up physicians to focus on patient care.
- · By automating routine procedures, SquareMind's platform can expand access to high-quality care.